Similar Papers

Paper Title
Journal
Date
Author
LBA16 - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
...
Annals of Oncology | VOL. 30
, et. al. ...
01 Nov 2019
1459PD - Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
J.F Vansteenkiste ... S.J Antonia
Annals of Oncology | VOL. 30
J.F Vansteenkiste, et. al.J.F Vansteenkiste ... S.J Antonia
01 Oct 2019
LBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
T.S.K Mok ... Y.-L Wu
Annals of Oncology | VOL. 30
T.S.K Mok, et. al.T.S.K Mok ... Y.-L Wu
01 Nov 2019
1542P - Safety of lorlatinib in subgroups of patients from a phase I/II trial
E Felip ... A.T Shaw
Annals of Oncology | VOL. 30
E Felip, et. al.E Felip ... A.T Shaw
01 Oct 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Marcela Carausu ... Michail Ignatiadis
Annals of Oncology | VOL. 36
Marcela Carausu, et. al.Marcela Carausu ... Michail Ignatiadis
01 Feb 2025
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
J.M Riedl ... R.B Corcoran
Annals of Oncology | VOL. -
J.M Riedl, et. al.J.M Riedl ... R.B Corcoran
01 Feb 2025
Whole genome sequencing powered ctDNA sequencing for breast cancer detection
I Garcia-Murillas ... N.C Turner
Annals of Oncology | VOL. -
I Garcia-Murillas, et. al.I Garcia-Murillas ... N.C Turner
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.